@article{e6e312be83014151b399b6cf2c327336,
title = "Bariatric surgery is associated with increased risk of new-onset inflammatory bowel disease: case series and national database study",
abstract = "Background: Case series suggest a possible association between bariatric surgery and incident IBD. Aim: The aim of this study was to evaluate the association between bariatric surgery and new-onset IBD. Methods: We first conducted a multi-institutional case series of patients with a history of IBD and bariatric surgery. We next conducted a matched case-control study using medical and pharmacy claims from 2008 to 2012 in a US national database from Source Healthcare Analytics LLC. Bariatric surgery was defined by ICD-9 or CPT code. Bariatric surgery was evaluated as recent (code in database timeframe), past (past history V code) or no history. Conditional logistic regression was used to estimate odds ratios (OR) and 95% CI for new-onset IBD, CD and UC. Results: A total of 15 cases of IBD (10 CD, 4 UC, 1 IBD, type unclassified) with a prior history of bariatric surgery were identified. Most cases were women, had Roux-en-Y surgery years prior to diagnosis and few IBD-related complications. A total of 8980 cases and 43 059 controls were included in our database analysis. Adjusting for confounders, a past history of bariatric surgery was associated with an increased risk of new-onset IBD (OR 1.93, 95% CI 1.34-2.79). However, patients who had recent bariatric surgery did not appear to be at shorter term risk of IBD (OR 0.94, 95% CI 0.58-1.52). Conclusion: New-onset IBD was significantly associated with a past history of bariatric surgery. This potential association needs to be confirmed in future prospective studies.",
author = "R. Ungaro and R. Fausel and Chang, {H. L.} and S. Chang and Chen, {L. A.} and A. Nakad and {El Nawar}, A. and {Prytz Berset}, I. and J. Axelrad and G. Lawlor and A. Atreja and {Roque Ramos}, L. and J. Torres and Colombel, {J. F.}",
note = "Funding Information: Crohn{\textquoteright}s and Colitis Foundation Career Development Award, Grant/Award Number: 455138; KL2 Scholar Award, Grant/Award Number: UL1TR000067 Funding Information: Declaration of personal interests: RU has served as a consultant and an advisory board member for Takeda, Pfizer, and Janssen. LAC has served as a consultant for Pfizer. GL has served as a speaker for Abbvie and Pfizer and an advisory board for member for Janssen. IPB has served as a speaker, a consultant and an advisory board member for the pharmaceutical companies AbbVie, Takeda, Hospira, MSD, Janssen Cilag, Ferring and Tillotts. LRR has served as a speaker for Janssen. JT has served as a speaker and consultant for Takeda and a consultant for Abbvie. JFC: Consultant or advisory board member for AbbVie, Amgen, Boehringer-Ingelheim, Arena Pharmaceuticals, Celgene Corporation, Celltrion, Enterome, Eli Lilly, Ferring Pharmaceuticals, Genentech, Janssen and Janssen, Medimmune, Merck & Co., Nextbiotix, Novartis Pharmaceuticals Corporation, Otsuka Pharmaceutical Development & Commercialization, Inc., Pfizer, Protagonist, Second Genome, Gilead, Seres Therapeutics, Shire, Takeda, Theradiag. Speaker for AbbVie, Ferring, Takeda, Celgene Corporation. Stock options: Intestinal Biotech Development, Genefit. Research Grants: AbbVie, Takeda, Janssen and Janssen. Other authors have no personal or funding interests to disclose. Declaration of funding interests: RCU is supported by a Crohn's and Colitis Foundation Career Development Award (455138) and a KL2 Scholar Award (UL1TR000067). Funding Information: Declaration of funding interests: RCU is supported by a Crohn{\textquoteright}s and Colitis Foundation Career Development Award (455138) and a KL2 Scholar Award (UL1TR000067). Publisher Copyright: {\textcopyright} 2018 John Wiley & Sons Ltd",
year = "2018",
month = apr,
doi = "10.1111/apt.14569",
language = "English",
volume = "47",
pages = "1126--1134",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "8",
}